jcicki , the food and drug administration ( fda ) is sending you this letter because you are marketing the 23andme saliva collection kit and personal genome service ( pgs ) without marketing clearance or approval in violation of the federal food , drug and cosmetic act ( the fd & c act ) . newline_char for example , your company ’ s website at www.23andme.com/health ( most recently viewed on november 6 , 2013 ) markets the pgs for providing “ health reports on 254 diseases and conditions , ” including categories such as “ carrier status , ” “ health risks , ” and “ drug response , ” and specifically as a “ first step in prevention ” that enables users to “ take steps toward mitigating serious diseases ” such as diabetes , coronary heart disease , and breast cancer . story_separator_special_tag the food and drug administration has ordered the maker of a popular genetic-testing kit to halt sales of its heavily marketed product , saying the mail-order tests haven ’ t been proven effective and could dangerously mislead people about their health . newline_char the company says that its personal genome service can detect more than 240 genetic conditions and traits , flagging a person ’ s vulnerability to heart disease , breast cancer and other illnesses . newline_char the fda said the company repeatedly has failed to provide the scientific data necessary to prove that its test works as advertised . newline_char perhaps more significantly , the agency ’ s action underscores its unease about the potential consequences of direct-to-consumer genetic tests , which can provide people with detailed information but not necessarily the context necessary to interpret what it means or how they should proceed . newline_char 22 but posted online monday , the fda said it was concerned about 23andme ’ s direct-to-consumer test “ because
